Human Longevity IPO

Human Longevity was founded in 2013 by J. Craig Venter, Peter Diamandis, and Robert Hariri. The company has not officially endorsed a plan to participate in an IPO. These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Human Longevity is a genomics-based health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype, and clinical data. The company's mission is "to extend healthy human life by revolutionizing human health and transforming the practice of medicine." The company has acquired Cypher Genomics and DoctorsForMe. Human Longevity, based in San Diego, has raised $330 million in venture capital funding from investors including Emerging Technology Partners, Threshold, StartUp Health, OS Fund, Illumina Ventures, GE Ventures, Celgene, and Amino Capital. The company has not disclosed recent valuation information, but in 2018 Human Longevity reported a significant drop in valuation, falling from $1.6 billion to $310 million.

Register for Details

For more details on financing and valuation for Human Longevity, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Human Longevity's ticker symbol?

Human Longevity does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Human Longevity's stock price?

The stock price for Human Longevity will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Human Longevity's major investors?

GE Ventures
Draper Fisher Jurvetson
Amino Capital
Synthetic Genomics
StartUp Health

Human Longevity Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
11/6/2019 Series A-2 $50.4MM $XXX.XX $XXX.XX
2/16/2017 Series A-1 $300MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Human Longevity

What is Human Longevity funding to date?

Human Longevity has raised $49.3MM with the following series:
$300MM for Series A-1, $50.4MM for Series A-2

When was Human Longevity founded?

Human Longevity was founded in 2013.

Can you invest in Human Longevity?

Human Longevity is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Human Longevity share pre-IPO?

If you own Human Longevity pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Is Human Longevity a publicly traded company?

Human Longevity is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Human Longevity in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation